Literature DB >> 30673953

Knowledge, attitudes, and perceived barriers towards genetic testing across three rural Illinois communities.

A J Fogleman1, W E Zahnd2, A E Lipka3, R S Malhi4, S Ganai5, K R Delfino6, W D Jenkins7.   

Abstract

Genetic testing is becoming more prevalent in detecting risk and guiding cancer treatment in our increasingly personalized medicine model. However, few studies have examined underserved populations' perceptions of genetic testing, especially those of rural dwelling populations. We asked residents of three rural communities to complete a self-administered survey gauging their knowledge, attitudes, and perceived barriers for genetic testing. 64.8% of participants of the overall study completed the survey. Most participants were aware of genetic testing for cancer screening (69.0%) and would likely share results with their family (88.5% if it indicated low risk, 85.9% for high risk). Some barriers were noted, including genetic testing not offered in a clinic nearby (46.9%), insurance company knowing the results (54.0%), cost (49.1%), and no accessible genetic counselors with whom to discuss results (45.6%). Our rural participants were generally knowledgeable about genetic testing, but this may not be reflective of all rural populations. Opportunities exist to mitigate use barriers, expand the utilization of telehealth services and regulatory agency-approved assays, and increase knowledge regarding privacy and protections offered by statute, such as the Genetic Information Nondiscrimination Act (US) and General Data Protection Regulation (Europe).

Entities:  

Keywords:  Genetic testing; Personalized medicine; Rural; Underserved population perceptions

Year:  2019        PMID: 30673953      PMCID: PMC6591342          DOI: 10.1007/s12687-019-00407-w

Source DB:  PubMed          Journal:  J Community Genet        ISSN: 1868-310X


  7 in total

1.  Applying Rogers' framework to evaluate public awareness and knowledge of medical genetics in a developing country.

Authors:  Hamid Asadollahi; Mahmoud Vakili; Reza Asadollahi
Journal:  J Community Genet       Date:  2020-02-28

2.  Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018.

Authors:  Mahip Acharya; Kristin K Zorn; Melinda E Simonson; Milan Bimali; Gary W Moore; Cheng Peng; Bradley C Martin
Journal:  Hered Cancer Clin Pract       Date:  2022-05-23       Impact factor: 2.164

3.  Distribution of Genomic Testing Resources by Oncology Practice and Rurality: A Nationally Representative Study.

Authors:  Brittany Gardner; Michelle Doose; Janeth I Sanchez; Andrew N Freedman; Janet S de Moor
Journal:  JCO Precis Oncol       Date:  2021-06-22

Review 4.  Cancer genetic testing in marginalized groups during an era of evolving healthcare reform.

Authors:  Stephen M Modell; Caitlin G Allen; Amy Ponte; Gail Marcus
Journal:  J Cancer Policy       Date:  2021-02-16

5.  Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer.

Authors:  Edward D Esplin; Sarah M Nielsen; Sara L Bristow; Judy E Garber; Heather Hampel; Huma Q Rana; N Jewel Samadder; Neal D Shore; Robert L Nussbaum
Journal:  JCO Precis Oncol       Date:  2022-09

6.  Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.

Authors:  Soyoun Rachel Kim; Alicia Tone; Raymond H Kim; Matthew Cesari; Blaise A Clarke; Lua Eiriksson; Tae L Hart; Melyssa Aronson; Spring Holter; Alice Lytwyn; Manjula Maganti; Leslie Oldfield; Steven Gallinger; Marcus Q Bernardini; Amit M Oza; Bojana Djordjevic; Jordan Lerner-Ellis; Emily Van de Laar; Danielle Vicus; Trevor J Pugh; Aaron Pollett; Sarah E Ferguson
Journal:  Cancer       Date:  2021-05-13       Impact factor: 6.860

7.  Cancer genetic testing in marginalized groups during an era of evolving healthcare reform.

Authors:  Stephen M Modell; Caitlin G Allen; Amy Ponte; Gail Marcus
Journal:  J Cancer Policy       Date:  2021-02-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.